Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

4.20USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,152
52-wk High
$5.67
52-wk Low
$2.40

Summary

Name Age Since Current Position

William Rastetter

68 Independent Chairman of the Board

J. Scott Wolchko

44 2015 President, Chief Executive Officer, Principal Executive Officer, Director

John Mendlein

57 Vice Chairman of the Board

Jim Beitel

2017 Senior Vice President - Corporate Development

Daniel Shoemaker

47 2015 Chief Scientific Officer

John Ferraro

2015 Vice President - Clinical Operations

Wendy Levin

2015 Vice President - Clinical Development

Walter Grubb

2015 Vice President - Business Development

Cindy Tahl

2009 General Counsel

Stewart Abbot

2015 Chief Development Officer

Chris Storgard

2016 Chief Medical Officer

Timothy Coughlin

50 2013 Independent Director

Mark Enyedy

53 2012 Independent Director

Robert Epstein

62 2014 Independent Director

Amir Nashat

44 2007 Independent Director

Biographies

Name Description

William Rastetter

Mr. William Rastetter, Ph.D., is Independent Chairman of the Board of Fate Therapeutics, Inc. He is a Co-Founder of Receptos, Inc., a biopharmaceutical company, where he has been a director and Chairman of the Board since May 2009 and was Acting Chief Executive Officer from May 2009 to November 2010. Dr. Rastetter served as a Partner at the venture capital firm of Venrock from 2006 to February 2013. Prior to that, Dr. Rastetter was Executive Chairman of Biogen Idec, from the merger of the two companies (Biogen and Idec Pharmaceuticals) in 2003 through the end of 2005. He joined Idec Pharmaceuticals at its founding in 1986 and served as Chairman and Chief Executive Officer. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and also served in a scientific capacity at Genentech. Dr. Rastetter also serves as the Chairman of Illumina, Inc. and Neurocrine Biosciences, Inc. and as a director of Regulus Therapeutics, Inc. Dr. Rastetter held various faculty positions at the Massachusetts Institute of Technology and Harvard University and was an Alfred P. Sloan Fellow. Dr. Rastetter holds a Ph.D. and M.A. in chemistry from Harvard University and an S.B. in chemistry from the Massachusetts Institute of Technology.

J. Scott Wolchko

Mr. J. Scott Wolchko has been appointed as President, Chief Executive Officer, Principal Executive Officer, Director of the Company. He was Chief Financial Officer, Chief Operating Officer of Fate Therapeutics, Inc. Mr. Wolchko began his career in 1994 as an investment banker with Morgan Stanley & Co., serving in the firm's New York City and Menlo Park, California offices. As a member of the firm's Investment Banking Health Care Group, he assisted emerging growth companies in the life sciences sector complete capital-raising and M&A transactions. Prior to joining us, from July 2001 to September 2007, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., an enterprise software company that specializes in data protection management. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.

John Mendlein

Dr. John Mendlein, Ph.D. is the Vice Chairman of the Board of Fate Therapeutics, Inc. Dr. Mendlein also serves as Executive Chairman and Chief Executive Officer of aTyr Pharma, Inc., a biopharmaceutical company, a position he has held since September 2011. He also holds board positions with Moderna Therapeutics and BIO (Biotechnology Industry Organization) including its emerging companies board. Dr. Mendlein previously served as the Chief Executive Officer of Adnexus Therapeutics, a biopharmaceutical company, from 2005 to 2008, which was purchased by Bristol-Myers Squibb (BMY) in 2008. Before that, he served as Chairman and Chief Executive Officer of Affinium Pharmaceuticals, Inc. from 2000 to 2005, and board member, General Counsel and Chief Knowledge Officer at Aurora Bioscience Corporation from August 1996 to September 2001. Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami.

Jim Beitel

Mr. Jim Beitel is Senior Vice President - Corporate Development of the Company. Mr. Beitel has more than 20 years of leadership experience in corporate development, strategy, sales and marketing, project management and finance with experience across the spectrum of life science companies. Mr. Beitel was previously Vice President of Corporate Development and Operations at Avanir Pharmaceuticals, where he facilitated the company's growth into a multi-product organization and the subsequent $3.5 billion acquisition of Avanir by Otsuka. Prior to Avanir, Mr. Beitel held various business development, sales and marketing, strategy and finance roles with increasing responsibility at Amgen, La Jolla Pharmaceutical Company and Zacharon Pharmaceuticals. Mr. Beitel holds a Master in Business Administration from Harvard Business School and a Bachelor of Science in Engineering from the University of Kansas.

Daniel Shoemaker

Dr. Daniel D. Shoemaker, Ph.D. is Chief Scientific Officer of the Company. He was Chief Research Officer since of the Company. He oversees our discovery and preclinical research efforts. He previously served as our Chief Technology officer since February 2009. From 2003 to 2009, Dr. Shoemaker was Chief Scientific Officer of ICxBiosystems, a biotechnology firm that develops advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. From 2003 to 2005, he was Chief Scientific Officer of GHC Technologies, a biotechnology company. From 1998 to 2003, Dr. Shoemaker held several positions at Merck Research Laboratories, including Director of Target Discovery, Senior Director at Rosetta Inpharmatics and research fellow in the Department of Molecular Neurosciences, where his main focus was on target identification and biomarker discovery. Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from the University of California, Santa Barbara.

John Ferraro

Mr. John Ferraro is Vice President - Clinical Operations of Fate Therapeutics, Inc. Mr. Ferraro joined Fate Therapeutics in February 2013, and will be responsible for the Company's clinical operations and data management functions. Prior to joining Fate, Mr. Ferraro was the Senior Director of Clinical Operations at GlobeImmune, Inc., where he established the clinical operations group and led the advancement of multiple targeted immunotherapies through the clinical development process in the United States and in Europe. Mr. Ferraro's professional experience spans 20 years of biopharmaceutical industry experience in global clinical operations and research positions at Pfizer and SmithKline Beecham.

Wendy Levin

Dr. Wendy Levin is Vice President - Clinical Development of Fate Therapeutics, Inc. Dr. Levin will play a critical role spearheading the Company's clinical development of PROHEMA® in patients with hematologic malignancies and rare genetic disorders. Dr. Levin, a board-certified hematologist / oncologist with extensive experience in clinical oncology research, joins Fate Therapeutics from MEI Pharma, where she was Vice President of Clinical Development and Medical Affairs. Previously, she held positions of increasing responsibilities at Pfizer from 2007 to 2013, where she led a global oncology program targeting the hedgehog pathway from first-in-human studies into later-stage development. Dr. Levin completed her Internal Medicine Residency at the University of Southern California, and went on to complete a Hematology / Oncology Fellowship at the University of Washington / Fred Hutchinson Cancer Research Center in Seattle.

Walter Grubb

Mr. Walter Grubb is Vice President - Business Development of Fate Therapeutics, Inc. Mr. Grubb's responsibilities will include the assessment, valuation and licensing of business opportunities for the Company. Mr. Grubb was previously Executive Director of Business Development and Commercial Operations at Ambit Biosciences, where he was responsible for multiple partnership transactions, provided commercial leadership for product candidates spanning a range of indications and stages of development, and was instrumental in the company's initial public offering and ultimate acquisition by Daiichi-Sankyo. Prior to Ambit, Mr. Grubb held positions of increasing responsibility at Neurocrine Biosciences from 2000 to 2008 that included business development, market analytics, medical affairs and product marketing.

Cindy Tahl

Ms. Cindy Tahl, J.D., is General Counsel of Fate Therapeutics, Inc. During her tenure at Fate Therapeutics, Ms. Tahl has served as the Company's senior legal counsel, providing legal advice across all functions of the business and overseeing all corporate compliance matters, and has led the development of the Company's intellectual property strategy. Ms. Tahl is admitted to the State Bars of California and New York.

Stewart Abbot

Dr. Stewart Abbot, Ph.D., Chief Development Officer is Chief Development Officer of Fate Therapeutics, Inc. Dr. Abbot joined Fate Therapeutics from Celgene Cellular Therapeutics (CCT), where he was instrumental in developing CCT's hematopoietic cell-based immuno-oncology programs and partnerships. In his capacity as Chief Development Officer, Dr. Abbot will lead early development strategy, and will be responsible for defining preclinical candidates and early development pathways and for advancing preclinical candidates into first-in-human clinical studies.

Chris Storgard

Dr. Chris M. Storgard, M.D. is Chief Medical Officer of the Company. He has more than 20 years of experience in clinical drug development, most recently serving as an integral member of the executive team at Ardea Biosciences, a member of the AstraZeneca Group. As Vice President of Clinical Research and Development at Ardea, Dr. Storgard led the ZURAMPIC® global clinical program to successful U.S. and European regulatory approvals.

Timothy Coughlin

Mr. Timothy P. Coughlin is Independent Director of Fate Therapeutics, Inc. He has served as Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc., a biopharmaceutical company, since September 2006, where he previously served as Vice President, Controller. Prior to joining Neurocrine in 2002, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as Vice President, Financial Services. Mr. Coughlin also served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors from 1989 to 1999. Mr. Coughlin holds a Master’s degree in international business from San Diego State University and a B.B.A. in accounting from Temple University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.

Mark Enyedy

Mr. Mark J. Enyedy is Independent Director of Fate Therapeutics, Inc. Mr. Enyedy is Senior Vice President and Head of the Internal Medicine business unit for Shire plc, a biopharmaceutical company, a position he has held since August 2013. Prior to Shire, from September 2011 to July 2013, Mr. Enyedy served as Chief Executive Officer and director of Proteostasis Therapeutics, Inc., a biopharmaceutical company. Prior to Proteostasis, he served 15 years with Genzyme Corporation, a biotechnology company, most recently as President of the Transplant, Oncology and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate in the business law department at Palmer & Dodge. Mr. Enyedy holds a J.D. from Harvard Law School and a B.S. in criminal justice from Northeastern University.

Robert Epstein

Dr. Robert S. Epstein, M.D. is Independent Director of the Company. Dr. Epstein is a strategic consultant to life sciences companies and an epidemiologist with extensive expertise in pharmacoeconomics and health outcomes research, having held various positions in academia and public health before joining the private sector. From 2010 to 2012, Dr. Epstein served as president of the Medco-UBC Division and as Chief Research and Development officer of Medco Health Solutions, Inc., a managed healthcare company. In these roles, Dr. Epstein was responsible for all of Medco's clinical research initiatives, including the Medco Research Consortium ("Medco") and United BioSource Corporation. Dr. Epstein served as Medco's Chief Medical Officer from 1997 to 2010, leading formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life, and was also elected to the AHRQ CERT (Centers for Education and Research on Therapeutics) Committee. In addition to Fate Therapeutics, Dr. Epstein serves on the Board of Directors of Illumina, Inc., AVEO Pharmaceuticals, Inc. and Proteus Digital Health, Inc.

Amir Nashat

Dr. Amir H. Nashat is Independent Director of Fate Therapeutics, Inc. He is also a Managing General Partner at Polaris Venture Partners. He joined Polaris in April 2002 and focuses on investments in healthcare, consumer products and energy. Dr. Nashat currently represents Polaris as a director of Receptos, Inc., as well as several private companies. Additionally, Dr. Nashat has served as a director of Adnexus Therapeutics (acquired by Bristol Myers Squibb) and other private companies. Dr. Nashat holds a Sc.D. in chemical engineering from the Massachusetts Institute of Technology with a minor in biology, and an M.S. and B.S. in materials science and mechanical engineering from the University of California, Berkeley.